Blood Coagulation Testing Instruments
Shareholders in Portfolio Company
Investment Started: 2010
1.08 bln rubles
Co-investment by RUSNANO0.58 bln rubles
Production of equipment and disposables for evaluating
blood-clotting disorders using a new diagnostic method
Portfolio company Hemacore is the embodiment of many years of fundamental scientific work. The company will bring to market a new diagnostic method that can forecast thromboses and potentially save millions from stroke and heart attacks. This diagnostic tool evaluates various phases of blood clotting and is without analogue in today’s medical instruments market.
The instrument can simultaneously analyze several blood samples; a diagnostic cycle requires only 30 minutes. Highly precise diagnoses, moderate test prices, and ease of use are expected to give this product a large share in the Russian market for coagulation analyzers and allow its producers to enter the international market.
Area of Application
- Clinical diagnostic laboratories and medical institutions
- Simultaneous diagnosis of insufficient (hemophilia) and excessive (thrombosis) blood clotting
- Ability to forecast thromboses
08 November 2012HemaCore’s New Blood Clotting Diagnostics Hits Market
Marchmont Innovation News
28 April 2010
Technologies and Products
The diagnostic procedure occurs in a cuvette, where the analyzer replicates the body’s natural mechanisms of blood coagulation. A digital camera tracks the blood clotting at the activator, which has a nanostructured coating of 30 nanometers to 50 nanometers that imitates the damaged wall of the blood vessel. The coating is a synthetic analogue of a phospholipid cell membrane with integrated thromboplastin protein molecules that initiates the blood clotting cascade.